Biosimilars: Facing the Hurdles and Opportunities of Therapeutic Oncology

Posted by Tucker Herbert on May 13, 2016 2:49:06 PM

Despite looming patent expirations, exact-copy “generics” are out of reach for breakthrough oncology drugs such as Rituxan, Herceptin, Avastin and Erbitux given the molecular complexity of biologic medicines. The closest achievable replications are called “biosimilars” because they have demonstrated bioequivalence and non-inferiority. While a few biosimilars have been on the market in Europe for a decade, significant skepticism remains, especially in the space of oncology therapeutics, which represents a $25 billion opportunity in annual revenue.

Read More